These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6737271)

  • 21. Determination of unbound fraction of disopyramide in plasma: a comparison of equilibrium dialysis, ultrafiltration through dialysis membranes and ultrafree anticonvulsant drug filters.
    Norris RL; Ahokas JT; Ravenscroft PJ
    J Pharmacol Methods; 1982 Jan; 7(1):7-14. PubMed ID: 7070107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors affecting the binding of disopyramide to serum proteins.
    Shaw LM; Altman R; Thompson BC; Fields L
    Clin Chem; 1985 Apr; 31(4):616-9. PubMed ID: 3884182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of (R)- and (S)-disopyramide in human plasma using a chiral alpha 1-acid glycoprotein column.
    Hermansson J; Eriksson M; Nyquist O
    J Chromatogr; 1984 Dec; 336(2):321-8. PubMed ID: 6530464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in the binding capacity of alpha-1-acid glycoprotein in patients with renal insufficiency.
    Kishino S; Nomura A; Di ZS; Sugawara M; Iseki K; Kakinoki S; Kitabatake A; Miyazaki K
    Ther Drug Monit; 1995 Oct; 17(5):449-53. PubMed ID: 8585106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of free disopyramide plasma concentrations using ultrafiltration and enzyme multiplied immunoassay.
    Raghow G; Meyer MC; Straughn AB
    Ther Drug Monit; 1985; 7(4):466-71. PubMed ID: 3909539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.
    Horiuchi T; Johno I; Hasegawa T; Kitazawa S; Goto M; Hata T
    Eur J Clin Pharmacol; 1989; 36(2):175-80. PubMed ID: 2721542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prazosin binding to human alpha 1-acid glycoprotein (orosomucoid), human serum albumin, and human serum. Further characterization of the 'single drug binding site' of orosomucoid.
    Brunner F; Müller WE
    J Pharm Pharmacol; 1985 May; 37(5):305-9. PubMed ID: 2862237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enantioselective binding of propranolol, disopyramide, and verapamil to human alpha(1)-acid glycoprotein.
    Hanada K; Ohta T; Hirai M; Arai M; Ogata H
    J Pharm Sci; 2000 Jun; 89(6):751-7. PubMed ID: 10824133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding of alfentanil to human alpha 1-acid glycoprotein, albumin and serum.
    Belpaire FM; Bogaert MG
    Int J Clin Pharmacol Ther Toxicol; 1991 Mar; 29(3):96-102. PubMed ID: 2071261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of age and smoking on the elimination of disopyramide.
    Bonde J; Pedersen LE; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Br J Clin Pharmacol; 1985 Nov; 20(5):453-8. PubMed ID: 4074615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereoselective binding of disopyramide to plasma proteins.
    Valdivieso L; Giacomini KM; Nelson WL; Pershe R; Blaschke TF
    Pharm Res; 1988 May; 5(5):316-8. PubMed ID: 3244643
    [No Abstract]   [Full Text] [Related]  

  • 32. [A comparison of alpha 1-acid glycoprotein (AAG) concentration and disopyramide binding in Chinese and Japanese].
    Jin EZ
    Hokkaido Igaku Zasshi; 1999 Jul; 74(4):279-88. PubMed ID: 10480035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melatonin high-affinity binding to alpha-1-acid glycoprotein in human serum.
    Morin D; Simon N; Deprés-Brummer P; Lévi F; Tillement JP; Urien S
    Pharmacology; 1997 May; 54(5):271-5. PubMed ID: 9380773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro protein binding behavior of dipyridamole.
    MacGregor TR; Sardi ED
    J Pharm Sci; 1991 Feb; 80(2):119-20. PubMed ID: 2051312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of blood collection technique on serum and plasma protein binding of disopyramide.
    Haughey DB; Lima JJ
    Eur J Clin Pharmacol; 1982; 22(2):185-9. PubMed ID: 7094989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Displacement of disopyramide from human plasma proteins.
    Pedersen LE; Bonde J
    Acta Pharmacol Toxicol (Copenh); 1985 Sep; 57(3):223-6. PubMed ID: 4061102
    [No Abstract]   [Full Text] [Related]  

  • 38. The acute changes in serum binding of disopyramide and flecainide after myocardial infarction.
    Caplin JL; Johnston A; Hamer J; Camm AJ
    Eur J Clin Pharmacol; 1985; 28(3):253-5. PubMed ID: 4007029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.
    Pedersen LE; Bonde J; Graudal NA; Backer NV; Hansen JE; Kampmann JP
    Br J Clin Pharmacol; 1987 Jan; 23(1):41-6. PubMed ID: 3814461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients.
    Chu JS; Kishion S; Nomura A; Miyazaki K
    Zhongguo Yao Li Xue Bao; 1997 Sep; 18(5):408-10. PubMed ID: 10322928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.